Study of IMC-S118AI in Type 1 Diabetes

Summary

This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.

Timeline

Start

2026-04

Primary completion

2030-11

Completion

2030-11

Drugs

Indications